Standard Chemotherapy versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients with Recurrent Glioblastoma Multiforme (GBM)

About this Study

The purpose of this study is to screen chemotherapy drugs currently used for the care of recurrent glioblastoma (a form of brain cancer) and to determine the most effective treatment based on results from a chemosensitivity assay which is a lab test that measures the number of tumor cells that are killed by a cancer drug.

Sponsor Protocol ID:CSCRGBM
IRB Number:2018-0139
Actively Enrolling
Interventional
Early Phase 1
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Men and Women and
  • Members of all ethnic groups
  • 18 years old at the time of enrollment
  •  Informed consent obtained and signed

Exclusion Criteria

  1. Pregnant women or nursing mothers cannot participate in the study. Women of childbearing age must have a negative pregnancy test within 72 hours prior to study entry. Women of childbearing potential must practice medically approved contraceptive precautions

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
Pavilion - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Anderson, Mark D, M.D.
How to participate in our Clinical Trials